Propanc Biopharma, Inc. financial data

Symbol
PPCB, PPCBD on OTC
Industry
Pharmaceutical Preparations
Location
302/6 Butler Street, Camberwell, Victoria, Australia
State of incorporation
DE
Fiscal year end
June 30
Former names
Propanc Health Group Corp (to 4/5/2017)
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.49 % -86.4%
Debt-to-equity -102 % +3.21%
Return On Equity 42.4 % -46.4%
Return On Assets -2.65K % -66.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 688M shares +4538%
Common Stock, Shares, Outstanding 688M shares +4538%
Entity Public Float 425K USD -42.5%
Common Stock, Value, Issued 688K USD +4538%
Weighted Average Number of Shares Outstanding, Basic 13.3K shares
Weighted Average Number of Shares Outstanding, Diluted 13.3K shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 234K USD +15.8%
General and Administrative Expense 916K USD -25%
Operating Income (Loss) -1.18M USD +18.3%
Nonoperating Income (Expense) -485K USD +58.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.67M USD +36.3%
Income Tax Expense (Benefit) -275 USD +84%
Net Income (Loss) Attributable to Parent -1.67M USD +33%
Earnings Per Share, Basic 1.53K USD/shares
Earnings Per Share, Diluted 1.53K USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.2K USD -30.4%
Assets, Current 18K USD -91.5%
Property, Plant and Equipment, Net 50 USD -95.4%
Operating Lease, Right-of-Use Asset 44.5K USD
Assets 78.5K USD -67.5%
Accounts Payable, Current 1.22M USD +5.66%
Employee-related Liabilities, Current 611K USD -2.14%
Liabilities, Current 4.15M USD +10.4%
Operating Lease, Liability, Noncurrent 24.9K USD
Liabilities 4.24M USD +11.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.49M USD +20.9%
Retained Earnings (Accumulated Deficit) -67.5M USD -2.56%
Stockholders' Equity Attributable to Parent -4.16M USD -16.7%
Liabilities and Equity 78.5K USD -67.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -236K USD +29.4%
Net Cash Provided by (Used in) Financing Activities 216K USD -38.4%
Common Stock, Shares Authorized 10B shares 0%
Common Stock, Shares, Issued 688M shares +4538%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.8K USD -245%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.61K USD -3.94%
Deferred Tax Assets, Valuation Allowance 11.5M USD +2.75%
Deferred Tax Assets, Gross 12.1M USD +2.51%
Depreciation 297 USD -82.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.43M USD +48%
Lessee, Operating Lease, Liability, to be Paid 7.3K USD -76.4%
Property, Plant and Equipment, Gross 23.6K USD -9.25%
Operating Lease, Liability, Current 21.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 20K USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 20.1K USD -16.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.78K USD -65.6%
Deferred Tax Assets, Operating Loss Carryforwards 9.08M USD +1.84%
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 61.9M USD +1.41%
Deferred Tax Assets, Net of Valuation Allowance 11.5M USD +2.75%
Interest Expense 690K USD +29.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%